InvestorsHub Logo
Followers 5
Posts 473
Boards Moderated 1
Alias Born 07/13/2006

Re: None

Friday, 08/04/2017 9:17:26 AM

Friday, August 04, 2017 9:17:26 AM

Post# of 59549
Imaging3 Announces Successful Conclusion of Mandatory Self-Remediation Period


Burbank, CA, July 27, 2017: Imaging3™, Inc. (OTCQB: IGNG) announced today that the three-year term of the mandatory self-remediation measures ordered against the company by the United States District Court in Los Angeles in connection with the consent agreement by and between the company and the SEC on July 25, 2014 is concluded. Dane Medley stated: “We are pleased with the progress we have made over the past three years. Against all odds, Imaging3 has overcome frivolous—yet expensive— shareholder litigation, restructured its debts, become current with all of its SEC reporting requirements, and raised much-needed capital, all with an unwavering focus on the task of bringing the revolutionary SmartScan™ imaging technology to market.

Scott Pancoast added: “Imaging3 has survived a gauntlet of issues over the past three years and has fought against many adversaries and non-believers. This company has always been focused, and will continue to stay focused, on the goal of delivering our superior imaging technology to the world’s healthcare stage.”

About Imaging3 Inc.

Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called SmartScan™, that will produce 3D x-ray images, virtually in real time. The SmartScan technology will allow healthcare professionals to perform diagnostic and therapeutic procedures more quickly and accurately, resulting in higher throughput for the clinicians and fewer safety risks for the patient. In addition, Imaging3’s technology exposes patients to significantly less harmful radiation than current imaging technologies such as CT scans, which the company believes will allow scans to be used in more pediatric applications than are currently prescribed. The technology also allows for greater portability, easier installation, and a significantly reduced cost burden for the healthcare system overall. Imaging3 is planning to submit a 510K application to the FDA during 2017 in order to gain approval to commercialize the SmartScan technology.

Visit the company’s website at http://www.imaging3.com for detailed information about the Company’s technology.

Safe Harbor Statement